EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interferon-primed immune landscapes predict immune-related adverse events during immune checkpoint inhibitor therapy

Juanjuan Kang, Rong Huang, Yumei Chen, Yang Yu, Xinyu Li, Xi Yong, Guangyu Ao, Qin Yang

Frontiers in Cell and Developmental Biology · 08.05.2026 · 14

DOI: 10.3389/fcell.2026.1798845 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 08.05.2026. Verfasst von Juanjuan Kang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Southwestern Chinese Medicine Resources, and Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Tra…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but frequently induce immune-related adverse events (irAEs), which can disrupt treatment and worsen outcomes. The mechanisms predisposing certain individuals to irAEs remain unclear, and reliable strategies for early prediction and prevention are urgently needed.

Methods

We analyzed pre-treatment peripheral blood mononuclear cell (PBMC) transcriptomic data from 88 patients receiving ICIs, including 22 who subsequently developed irAEs. Immune infiltration signatures were used to build machine learning models with SHAP-based interpretability. Immune-related differentially expressed genes were then incorporated into the Chemical-Induced Gene Signature (CIGS) framework to predict candidate reversal compounds. Selected compounds were further evaluated in Jurkat T cells to experimentally validate their effects on interferon-γ signaling and underlying mechanisms.

Results

Baseline immune infiltration patterns showed strong predictive value for subsequent irAE development, with the Random Forest model achieving the best performance (AUC = 0.97). SHAP analysis revealed that activated T-cell and NK-cell signatures were dominant predictors, indicating a pre-existing immune-primed state in irAE-prone individuals. Single-cell analysis identified two irAE-enriched myeloid clusters with lung-associated inflammatory features, suggesting baseline myeloid priming. T cells and NK cells from irAE samples exhibited marked upregulation of interferon-stimulated genes and strong enrichment of type I and type II interferon pathways. Perturbation-based screening identified multiple compounds capable of reversing these interferon-amplified signatures, and in vitro experiments demonstrated that alpinetin and momelotinib suppress interferon-γ signaling through distinct STAT1-and JAK–STAT–dependent mechanisms. Conclusion irAEs may arise from the convergence of pre-existing myeloid inflammation and interferon-driven lymphocyte activation before therapy. Our study provides a predictive framework for identifying high-risk patients and highlights mechanistically grounded compounds for potential irAE mitigation.

Schlagwörter

Stichwörter der Autor:innen

drug repurposingimmune checkpoint inhibitorimmune-related adverse eventsinterferon signalingmachine learning

Autor:innen und Institutionen

  • State Key Laboratory of Southwestern Chinese Medicine Resources, and Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
  • School of Pharmacy, North Sichuan Medical College, Nanchong, China.
  • Affiliated Hospital of Clinical School of Medicine, North Sichuan Medical College, Institute of Neurological Diseases, Nanchong, China.
  • School of Intelligent Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
  • Department of Vascular Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
  • Sichuan Branch of National Clinical Research Center for Digestive Diseases, Nanchong, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Kang, J., Huang, R., Chen, Y., Yu, Y., Li, X., Yong, X., Ao, G., & Yang, Q. (2026). Interferon-primed immune landscapes predict immune-related adverse events during immune checkpoint inhibitor therapy. Frontiers in Cell and Developmental Biology, 14. https://doi.org/10.3389/fcell.2026.1798845

Vancouver

Kang J, Huang R, Chen Y, Yu Y, Li X, Yong X, et al. Interferon-primed immune landscapes predict immune-related adverse events during immune checkpoint inhibitor therapy. Frontiers in Cell and Developmental Biology. 2026;14. doi:10.3389/fcell.2026.1798845

BibTeX
@article{Kang2026,
  author = {Kang, Juanjuan and Huang, Rong and Chen, Yumei and Yu, Yang and Li, Xinyu and Yong, Xi and Ao, Guangyu and Yang, Qin},
  title = {Interferon-primed immune landscapes predict immune-related adverse events during immune checkpoint inhibitor therapy},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2026},
  volume = {14},
  doi = {10.3389/fcell.2026.1798845}
}
Kostenlos starten →